PROTONIX Drug Patent Profile

Which patents cover Protonix, and when can generic versions of Protonix launch?

Protonix is a drug marketed by Wyeth Pharms and is included in three NDAs. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has thirty-five patent family members in twenty-eight countries.

The generic ingredient in PROTONIX is pantoprazole sodium. There are forty-eight drug master file entries for this compound. Sixty-six suppliers are listed for this compound. Additional details are available on the pantoprazole sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Protonix

A generic version of PROTONIX was approved as pantoprazole sodium by APOTEX on January 19^th, 2011.

Summary for PROTONIX

International Patents:	35
US Patents:	1
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	32
Patent Applications:	4,084
Drug Prices:	Drug price information for PROTONIX
Drug Sales Revenues:	Drug sales revenues for PROTONIX
What excipients (inactive ingredients) are in PROTONIX?	PROTONIX excipients list
DailyMed Link:	PROTONIX at DailyMed

See drug prices for PROTONIX

See drug sales revenues for PROTONIX

Recent Clinical Trials for PROTONIX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pfizer	Phase 2
Mirati Therapeutics Inc.	Phase 1
Assiut University	Phase 2

See all PROTONIX clinical trials

Pharmacology for PROTONIX

Drug Class	Proton Pump Inhibitor
Mechanism of Action	Proton Pump Inhibitors

Paragraph IV (Patent) Challenges for PROTONIX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PROTONIX	for Delayed-release Oral Suspension	pantoprazole sodium	40 mg	022020	1	2019-09-13
PROTONIX	Delayed-release Tablets	pantoprazole sodium	20 mg and 40 mg	020987		2004-02-02

US Patents and Regulatory Information for PROTONIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Pharms	PROTONIX	pantoprazole sodium	FOR SUSPENSION, DELAYED RELEASE;ORAL	022020-001	Nov 14, 2007	AB	RX	Yes	Yes					Y
Wyeth Pharms	PROTONIX IV	pantoprazole sodium	INJECTABLE;INTRAVENOUS	020988-001	Mar 22, 2001	AP	RX	Yes	Yes
Wyeth Pharms	PROTONIX	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	020987-002	Jun 12, 2001	AB	RX	Yes	No
Wyeth Pharms	PROTONIX	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	020987-001	Feb 2, 2000	AB	RX	Yes	Yes

Expired US Patents for PROTONIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Wyeth Pharms	PROTONIX	pantoprazole sodium	FOR SUSPENSION, DELAYED RELEASE;ORAL	022020-001	Nov 14, 2007
Wyeth Pharms	PROTONIX	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	020987-002	Jun 12, 2001
Wyeth Pharms	PROTONIX	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	020987-001	Feb 2, 2000
Wyeth Pharms	PROTONIX	pantoprazole sodium	FOR SUSPENSION, DELAYED RELEASE;ORAL	022020-001	Nov 14, 2007
Wyeth Pharms	PROTONIX	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	020987-002	Jun 12, 2001

International Patents for PROTONIX

See the table below for patents covering PROTONIX around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	86894	Dialkoxyridines, process for their preparation, their application and medicaments containing them
Israel	174432	PANTOPRAZOLE MULTIPARTICULATE FORMULATIONS
China	1886119	Pantoprazole multiparticulate formulations
Bulgaria	61796
South Africa	8504287

Supplementary Protection Certificates for PROTONIX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0166287	SPC/GB96/056	United Kingdom		PRODUCT NAME: PANTOPRAZOLE AND ITS SALTS, HYDRATES AND HYDRATES OF ITS SALTS; REGISTERED: SE SE12131 19940506; UK 04889/0010 19960604
0166287	96C0032	Belgium		PRODUCT NAME: PANTOPRAZOL. NATR. SESQUIHYDRAS PANTOPRAZOLE; NAT. REGISTRATION NO/DATE: 127 IS 98 F 3 19960222; FIRST REGISTRATION: SE 12131 19940506
0166287	96C0033	Belgium		PRODUCT NAME: EPTACOG ALFA (ACTIVATED); REGISTRATION NO/DATE: EU/1/96/006/002 19960223

Market Dynamics and Financial Trajectory for Protonix (Pantoprazole)

Last updated: February 20, 2026

Protonix, a proton pump inhibitor (PPI) branded as pantoprazole, has maintained a significant position in the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, and related acid-related disorders. This report analyzes current market conditions, competitive landscape, regulatory environment, and revenue projections.

Market Overview

The global PPI market was valued at approximately USD 11.5 billion in 2022. Expected compound annual growth rate (CAGR) over the next five years approximates 4.5%, driven by increasing prevalence of acid-related disorders and an expanding aging population.

Key products besides Protonix include:

• Nexium (esomeprazole), manufacturer AstraZeneca
• Prilosec (omeprazole), manufacturer AstraZeneca
• Lansoprazole, generic and brand
• Aventis's AcipHex (rabeprazole)

Protonix Market Share

Protonix holds around 9% of the global PPI market, with revenue peaks in 2015-2016 following its patent exclusivity. Since patent expiry in 2018, generic pantoprazole acquisitions and sales surged, reducing revenue from original formulations.

Year	Brand Protonix Revenue (USD millions)	Generic Market Share (%)
2015	800	50
2018	650	75
2022	300	85

Source: IQVIA, 2022.

Patent and Regulatory Environment

The original patent for Protonix expired in 2018, enabling generics. Teva Pharmaceuticals, Mylan, and other players launched generic pantoprazole products shortly after.

U.S. FDA approvals of generic versions provided immediate price erosion and volume increases. The branded drug's exclusivity period ended earlier due to patent challenges, but some formulations retained market presence through REMS (Risk Evaluation and Mitigation Strategy) designations and formulation differences.

Competitive Landscape

Generic drugs now comprise over 80% of PPI prescriptions. Leading generics include:

• Mylan's (now Viatris) pantoprazole sodium
• Teva's pantoprazole magnesium
• Sandoz's equivalent formulations

Innovative launches include combination drugs and delayed-release formulations. No comprehensive new molecular entities (NMEs) for proton pump inhibitors have entered the market since 2012, limiting innovative revenue growth.

Revenue Trajectory and Future Outlook

Historical Revenue Trends

Year	Protonix (Brand) Revenue	Generic Sales Revenue	Total PPI Revenue
2018	USD 650 million	USD 4 billion	USD 4.65 billion
2019	USD 550 million	USD 4.2 billion	USD 4.75 billion
2020	USD 400 million	USD 4.5 billion	USD 4.9 billion
2021	USD 350 million	USD 4.7 billion	USD 5.05 billion

The decline reflects generic market penetration.

Projections (2023-2027)

• Branded Protonix revenues expected to decline further, reaching USD 150-200 million annually by 2025.
• Overall PPI market projected to grow modestly at 4-5%, driven by new indications, off-label uses, and expanding markets.
• Generic volume will dominate, maintaining low single-digit profit margins.

Revenue sources are shifting from branded to generic sales, with branded revenue representing less than 3% of total market share as of 2022.

Potential Catalysts

• New formulations with improved bioavailability or reduced side effects.
• Indications for conditions beyond GERD, including H. pylori eradication and Barrett’s esophagus.
• Biosimilar developments and market entry of novel acid-suppressing medications.

Key Challenges

• Price erosion due to generics.
• Patent litigation and legal challenges delaying any substantial branded rebound.
• Market saturation in developed economies.

Strategic Considerations

• Brands aiming to retain market share should diversify through combination therapies and line extensions.
• R&D investments in novel delivery mechanisms or combination drugs may combat commoditization.
• Companies should monitor regulatory changes affecting biosimilar approval pathways.

Key Takeaways

• Protonix's revenue has declined markedly since patent expiry, with generics dominating the market.
• The PPI market grows slowly, constrained by generics and patent challenges.
• Future growth depends on innovation, new indications, and strategic positioning within a commoditized landscape.
• Branded Protonix revenues will likely diminish to less than USD 200 million by 2025, with total industry revenues expanding modestly due to generics.

FAQs

1. Will Protonix regain market share or revenue growth?
Unlikely, due to patent expiration and generic competition; small incremental gains are possible through line extensions or new formulations.

2. How does Protonix compare to other PPIs in revenue?
It trails Nexium and Prilosec, which have larger market shares and broader indications, especially in the U.S.

3. Are there upcoming patent litigations that might impact Protonix?
Most patent challenges concluded by 2018, with limited further litigation expected.

4. What are the primary drivers for PPI market growth?
Increases in GERD prevalence, aging populations, and off-label uses.

5. How significant is the generic segment for Protonix sales?
The majority of PPI prescriptions are generic; Protonix's branded sales account for less than 5% of total revenue in the segment.

---

Sources:

1. IQVIA, 2022. "Global Proton Pump Inhibitors Market Report."
2. U.S. Food and Drug Administration (FDA), 2018. "Approval for Generic Pantoprazole."
3. MarketWatch, 2023. "Protonix Revenue and Market Share Data."
4. EvaluatePharma, 2022. "Pharmaceutical Industry Revenue Trends."
5. U.S. Patent and Trademark Office, 2018. "Patent Expirations and Challenges."